Provided by Tiger Fintech (Singapore) Pte. Ltd.

Amgen

277.47
+4.391.61%
Volume:750.19K
Turnover:206.68M
Market Cap:149.38B
PE:22.69
High:277.47
Open:274.14
Low:273.28
Close:273.09
52wk High:339.17
52wk Low:253.30
Shares:538.36M
Float Shares:536.99M
Volume Ratio:0.47
T/O Rate:0.14%
Dividend:9.26
Dividend Rate:3.34%
EPS(TTM):12.23
EPS(LYR):7.62
ROE:99.14%
ROA:7.51%
PB:20.11
PE(LYR):36.43

Loading ...

Amgen Inc. Stock Underperforms Thursday When Compared To Competitors Despite Daily Gains

Dow Jones
·
Sep 12

Handan City Market Supervision Bureau in Hebei Province Organizes "Party Member Double Registration, Drug Safety into Ten Thousand Homes" Science Education Campaign

Deep News
·
Sep 11

Amgen Rocatinlimab's Data Shows Potential As Long-Term Therapy For Atopic Dermatitis

Benzinga_recent_news
·
Sep 10

Amgen and Kyowa Kirin Announce Top-Line Results From Rocatinlimab Phase 3 Ascend Long-Term Extension Study in Adults With Moderate to Severe Atopic Dermatitis

THOMSON REUTERS
·
Sep 09

Verizon, Merck Share Losses Contribute To Dow's 118-Point Drop

Dow Jones
·
Sep 08

Hansoh Pharmaceutical Secures NMPA Approval for New Indication of XINYUE (Inebilizumab) for IgG4-Related Disease

Reuters
·
Sep 06

Amgen Inc. Stock Underperforms Thursday When Compared To Competitors

Dow Jones
·
Sep 05

Amgen Faces Setback As Final Data Weakens Case For Gastric Cancer Drug

Benzinga
·
Sep 05

Amgen Announces Promising Phase 2 Study Results for New Obesity Drug MariTide, Paving Way for Phase 3 Trials

Reuters
·
Sep 04

Amgen Coverage Assumed by Raymond James at Market Perform

Dow Jones
·
Sep 04

ZAI LAB (09688): Latest Update on Amgen's Bemarituzumab FORTITUDE-101 Phase III Clinical Trial

Stock News
·
Sep 03

Zai Lab Ltd. Awaits Results from FORTITUDE-102 Trial for Bemarituzumab in Gastric Cancer Treatment Following Attenuated Survival Benefit in Phase 3 FORTITUDE-101 Study

Reuters
·
Sep 03

Amgen Inc : Raymond James Assumes Coverage With Market Perform Rating

THOMSON REUTERS
·
Sep 03

Amgen to Invest $600 Million at California Headquarters

Dow Jones
·
Sep 02

Amgen to Invest Over $600 Million in Science and Innovation Center at California HQ

MT Newswires Live
·
Sep 02

Amgen Investing More Than Half a Billion Dollars in New, State-of-the-Art Center for Science and Innovation at U.S. Global Headquarters

THOMSON REUTERS
·
Sep 02

BRIEF-Amgen To Invest Over $600 Million In New Center For Science & Innovation In California

Reuters
·
Sep 02

Amgen Inc- Plans to Invest Over $600 Mln in New Center for Science & Innovation in Thousand Oaks, California

THOMSON REUTERS
·
Sep 02

Amgen Inc- Research & Development Infrastructure Investment Expected to Create Hundreds of U.S. Jobs

THOMSON REUTERS
·
Sep 02

Hansoh Pharmaceutical Group Co. Ltd. Secures NMPA Approval for Second Indication of XINYUE (Inebilizumab Injection) for IgG4-Related Disease

Reuters
·
Sep 01